Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions
Source link
Home Healthcare Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session...